GALECTIN-3 — BIOMARKER OF FIBROSIS IN PATIENTS WITH METABOLIC SYNDROME
https://doi.org/10.15829/1560-4071-2015-9-96-102
Abstract
Recent decades there was a growing amount of people with obesity, hence the amount of the associated pathologies such as arterial hypertension, heart failure, non-alcoholic fatty liver disease. In obesity the most common for all diseases is a chronic “smoldering” inflammation. Inflammatory reaction can be a cause of apoptosis and/or necrosis of the cells (cardiomyocytes, hepatocytes, pancreocytes, endoteliocytes). Terminal pathway of chronic inflammation and tissues damage is usually related to fibrosis — the most common and widespread outcome of many diseases. An important issue is diagnostics of fibrosis at early stages. The main interest for the study is focused on noninvasive assessment of fibrosis at early stages, e. g. the levels of galectin-3. This marker is regarded as possible profibrotic molecule, potential marker of liver and heart fibrosis. Perhaps the investigation on galectin-3 might help in evaluation of the risk of fibrosis development and progression assessment.
About the Authors
O. M. Drapkina
I.M. Sechenov First Moscow State Medical University. Clinics of Internal Diseases Propedeutics
Russian Federation
Russian Federation
T. A. Deeva
I.M. Sechenov First Moscow State Medical University. Clinics of Internal Diseases Propedeutics
Russian Federation
Russian Federation
References
1. Korneeva ON, Drapkina OM. Ursodeoxycholic acid and statins in the treatment of metabolic syndrome. Russian Medical News. 2007; 3: 26-31. Russian (Корнеева О. Н., Драпкина О. М. Урсодезоксихолевая кислота и статины при лечении метаболического синдрома. Рос. мед. вести. 2007; 3: 26-31).
2. Issa R, Rich CB, Foster JA, et al. Spontaneous recovery from micronodular cirrhosis: evidence for incomplete resolution associated with matrix crosslinking. Gastroenterology. 2004; 126: 1795-808.
3. Liu F, Patterson RJ, Wang JL. Intracellular function of galectins. BBA General Subjects 2002; 1572 (2-3): 263-73.
4. Dumic J, Dabelic S, Flogel M. Galectin-3: an open-ended story. Biochim Biophys Acta 2006; 1760: 616-35.
5. Henderson NC, Sethi T. The regulation of inflammation by galectin-3. Immunol Rev 2009; 230 (1): 160-71.
6. Bik MA. The role of galektin-3 and galektin-9 in the chronic inflammation of rheumatoid arthritis. A thesis submitted to The University of Birmingham for the degree of Doctor of Philosophy: 1-194.
7. Hoyer KK, Pang M, Gui D, et al. An antiapoptotic role for galectin-3 in diffuse large B-cell lymphomas. Am J Pathol. 2004, 164: 893-902.
8. Lin HM, Moon BK, Yu F, Kim HR. Galectin-3 mediates genisteininduced G(2)/M arrest and inhibits apoptosis. Carcinogenesis 2000; 21: 1941-5.
9. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis treatment of acute, chronic heart failure 2008. The task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008; 10: 933-89. 1
10. Cowie MR, Collinson PO, Dargie H, et al. Recommendations on the clinical use of B-type natriuretic peptide testing (BNP or NTproBNP) in the UK and Ireland. Br J Cardiol, 2010; 17, 2, 17: 76-80.
11. Drapkina OM, Dubolazova YV. Features of the pulse wave in patients with arterial hypertension and heart failure with preserved ejection fraction. Russian Medical News, 2012; XVII, 4: 20-31. Russian (Драпкина О.М., Дуболазова Ю.В. Характеристики пульсовой волны у пациентов c артериальной гипертензией и сердечной недостаточностью с сохраненной фракцией выброса. Российские Медицинские Вести, 2012; XVII, 4: 20-31).
12. Felker GM, Fiuzat M, Shaw LK, et al. Prognostic value of galectin-3 in chronic heart failure: results from the HF-ACTION study. Eur Heart J 2010; 31(Suppl 1): 429.
13. de Boer RA, Lok D, Hillege JL, et al. Clinical and prognostic value of galectin-3, a novel fibrosis-associated biomarker. Relation with clinical and biochemical correlates of heart failure, J Am Coll Cardiol. 2010; 55: A26.
14. Lok DJA, van der Meer P, Bruggink-Andre´ de la Porte PW, et. al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. ClinResCardiol 2010; 99: 323-8.
15. Henderson NC, at all. Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci USA. Mar 28, 2006; 103(13): 5060-5.
Review
For citations:
Drapkina O.M., Deeva T.A. GALECTIN-3 — BIOMARKER OF FIBROSIS IN PATIENTS WITH METABOLIC SYNDROME. Russian Journal of Cardiology. 2015;(9):96-102. (In Russ.) https://doi.org/10.15829/1560-4071-2015-9-96-102
Views:
4630
Email this article 